|Day's Range||1.29 - 1.31|
|52 Week Range||1.22 - 2.24|
|PE Ratio (TTM)||-5.95|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Deploying a suspension of cells generated from a ReCell® medical device onto a skin donor site can speed up healing by 30.7% and deliver a superior final outcome, according to the results of a randomized controlled trial involving 106 patients who received skin grafts, Avita Medical , said today.
The board of pioneering regenerative medicine company Avita Medical Limited has appointed Dr Michael Perry as its new Chief Executive Officer.
The board of pioneering regenerative medicine company Avita Medical Limited , have shown a strong vote of confidence in the company by taking part or all of their Director’s fees in the form of shares.